Published: Feb 16, 2021 Pulse Biosciences Announces Start of Controlled Launch of the CellFX System ® - First Aesthetic Dermatology Patients Treated in the U.S.
HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced that the first clinic patients have been treated with the CellFX ® System. This first commercial use of the CellFX System marks the initiation of the Company’s controlled launch program with product shipments to respected leaders in dermatology in the U.S. and in Europe. The CellFX System for cellular-based skin conditions (Photo: Pulse Biosciences)